These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11477561)

  • 21. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
    Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
    J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases.
    Maiorana A; Cesinaro AM; Fano RA; Collina G
    Clin Exp Metastasis; 1995 Jan; 13(1):43-8. PubMed ID: 7820955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease.
    Braun S; Hepp F; Sommer HL; Pantel K
    Int J Cancer; 1999 Feb; 84(1):1-5. PubMed ID: 9988223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.
    Braun S; Kentenich C; Janni W; Hepp F; de Waal J; Willgeroth F; Sommer H; Pantel K
    J Clin Oncol; 2000 Jan; 18(1):80-6. PubMed ID: 10623696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation.
    Pantel K; Enzmann T; Köllermann J; Caprano J; Riethmüller G; Köllermann MW
    Int J Cancer; 1997 May; 71(4):521-5. PubMed ID: 9178803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Isolated tumor cells in bone marrow predicts reduced survival in lymph node-negative non-small-cell lung cancer].
    Passlick B; Kubuschok B; Izbicki JR; Thetter O; Pantel K
    Pneumologie; 2000 Aug; 54(8):355-60. PubMed ID: 11008478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
    Allgayer H; Heiss MM; Riesenberg R; Grützner KU; Tarabichi A; Babic R; Schildberg FW
    Cancer Res; 1997 Apr; 57(7):1394-9. PubMed ID: 9102229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunocytochemical detection and prognostic significance of epithelial tumor cells in bone marrow of patients with pancreatic carcinoma].
    Thorban S; Roder JD; Pantel K; Siewert JR
    Zentralbl Chir; 1996; 121(6):487-9; discussion 490-2. PubMed ID: 8767337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells.
    Riesenberg R; Oberneder R; Kriegmair M; Epp M; Bitzer U; Hofstetter A; Braun S; Riethmüller G; Pantel K
    Histochemistry; 1993 Jan; 99(1):61-6. PubMed ID: 7682210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer.
    Bijen CB; Bantema-Joppe EJ; de Jong RA; Leffers N; Mourits MJ; Eggink HF; van der Zee AG; Hollema H; de Bock GH; Nijman HW
    Int J Cancer; 2010 Mar; 126(6):1417-27. PubMed ID: 19728333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
    Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
    Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human leukocyte antigen G expression in breast cancer: role in immunosuppression.
    Elliott RL; Jiang XP; Phillips JT; Barnett BG; Head JF
    Cancer Biother Radiopharm; 2011 Apr; 26(2):153-7. PubMed ID: 21510769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rating of isolated disseminated tumor cells in bone marrow in comparison with other factors of prognosis in breast carcinoma.
    Leinung S; Würl P; Schönfelder A; Weiss CL; Röder I; Schönfelder M
    Int J Surg Investig; 2000; 2(3):193-202. PubMed ID: 12678519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
    Wintzer HO; Benzing M; von Kleist S
    Br J Cancer; 1990 Aug; 62(2):289-95. PubMed ID: 2201398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered expression of HLA class I antigens in breast cancer: association with prognosis.
    Gudmundsdóttir I; Gunnlaugur Jónasson J; Sigurdsson H; Olafsdóttir K; Tryggvadóttir L; Ogmundsdóttir HM
    Int J Cancer; 2000 Nov; 89(6):500-5. PubMed ID: 11102894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma.
    Janni W; Gastroph S; Hepp F; Kentenich C; Rjosk D; Schindlbeck C; Dimpfl T; Sommer H; Braun S
    Cancer; 2000 May; 88(10):2252-9. PubMed ID: 10820346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.
    Saio M; Teicher M; Campbell G; Feiner H; Delgado Y; Frey AB
    Clin Exp Metastasis; 2004; 21(3):243-9. PubMed ID: 15387374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disseminated epithelial tumor cells in bone marrow of patients with esophageal cancer: detection and prognostic significance.
    Thorban S; Roder JD; Nekarda H; Funk A; Pantel K; Siewert JR
    World J Surg; 1996 Jun; 20(5):567-72; discussion 572-3. PubMed ID: 8661632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.
    Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Krajewski S; Sommer H; Friese K
    Breast Cancer Res Treat; 2007 Jan; 101(1):17-25. PubMed ID: 16807671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major histocompatibility complex class I-restricted alloreactive CD4+ T cells.
    Boyle LH; Goodall JC; Gaston JS
    Immunology; 2004 May; 112(1):54-63. PubMed ID: 15096184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.